{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T05:09:44Z","timestamp":1789967384018,"version":"4.0.1"},"reference-count":29,"publisher":"Public Library of Science (PLoS)","issue":"1","license":[{"start":{"date-parts":[[2017,1,12]],"date-time":"2017-01-12T00:00:00Z","timestamp":1484179200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0169761","type":"journal-article","created":{"date-parts":[[2017,1,12]],"date-time":"2017-01-12T16:15:07Z","timestamp":1484237707000},"page":"e0169761","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":64,"title":["Economic Evaluation of PCSK9 Inhibitors in Reducing Cardiovascular Risk from Health System and Private Payer Perspectives"],"prefix":"10.1371","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7628-8894","authenticated-orcid":true,"given":"Alejandro","family":"Arrieta","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy F.","family":"Page","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emir","family":"Veledar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khurram","family":"Nasir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2017,1,12]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"40","DOI":"10.7326\/M14-2957","article-title":"Effects of proprotein convertase subtilisin\/kexin type 9 antibodies in adults with hypercholesterolemia: a systematic review and meta-analysis","volume":"163","author":"EP Navarese","year":"2015","journal-title":"Ann Intern Med"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"2638","DOI":"10.1016\/j.jacc.2015.05.001","article-title":"Are PCSK9 inhibitors the next breakthrough in the cardiovascular field?","volume":"65","author":"RP Giugliano","year":"2015","journal-title":"J Am Coll Cardiol"},{"key":"ref3","unstructured":"US Food and Drug Administration. FDA approves Repatha to treat certain patients with high cholesterol. 2015. http:\/\/www.fda.gov\/NewsEvents\/Newsroom\/PressAnnouncements\/ucm460082.htm<\/ext-link>."},{"key":"ref4","unstructured":"US Food and Drug Administration. FDA approves Praluent to treat certain patients with high cholesterol. 2015. http:\/\/www.fda.gov\/NewsEvents\/Newsroom\/PressAnnouncements\/ucm455883.htm<\/ext-link>."},{"key":"ref5","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1056\/NEJMoa1500858","article-title":"Efficacy and safety of evolocumab in reducing lipids and cardiovascular events","volume":"372","author":"MS Sabatine","year":"2015","journal-title":"N Engl J Med"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1056\/NEJMp1509863","article-title":"Specialty pharmaceuticals for hyperlipidemia\u2014impact on insurance premiums","volume":"373","author":"KA Schulman","year":"2015","journal-title":"N Engl J Med"},{"key":"ref7","unstructured":"Shrank W, Lotvin A, Singh S, Brennan T. In the debate about cost and efficacy, PCSK9 inhibitors may be the biggest challenge yet. 2015. http:\/\/healthaffairs.org\/blog\/2015\/02\/17\/in-the-debate-about-cost-and-efficacy-pcsk9-inhibitors-may-be-the-biggest-challenge-yet\/<\/ext-link>."},{"key":"ref8","first-page":"SP456","article-title":"For Now, PBMs Just Say No to High-Cost PCSK9 Inhibitors","volume":"21","author":"M Caffrey","year":"2015","journal-title":"American journal of managed care"},{"key":"ref9","unstructured":"Tice JA, Ollendorf DA, Cunningham C, Pearson SD, Kazi DS, Coxson PG. PCSK9 inhibitors for treatment of high cholesterol: effectiveness, value, and value-based price benchmarks: final report. The Institute for Clinical and Economic Review (ICER). 2015."},{"key":"ref10","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1001\/jamainternmed.2015.7248","article-title":"Proprotein convertase subtilisin\/kexin type 9 (pcsk9) inhibitors for treatment of high cholesterol levels: effectiveness and value","volume":"176","author":"JA Tice","year":"2016","journal-title":"JAMA internal medicine"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1001\/jama.2016.11004","article-title":"Cost-effectiveness of PCSK9 inhibitor therapy in patients with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease","volume":"316","author":"DS Kazi","year":"2016","journal-title":"JAMA"},{"key":"ref12","article-title":"Cost-Effectiveness of LDL-C Lowering With Evolocumab in Patients With High Cardiovascular Risk in the United States","author":"SR Gandra","year":"2016","journal-title":"Clin Cardiol"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1161\/HYPERTENSIONAHA.114.03780","article-title":"Cost\u2013Benefit Analysis of Home Blood Pressure Monitoring in Hypertension Diagnosis and Treatment: An Insurer Perspective","volume":"64","author":"A Arrieta","year":"2014","journal-title":"Hypertension"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1377\/hlthaff.22.2.17","article-title":"The business case for quality: case studies and an analysis","volume":"22","author":"S Leatherman","year":"2003","journal-title":"Health Aff"},{"key":"ref15","unstructured":"Lakdawalla D, Neumann PJ. Budget Criteria And Drug Value Assessments: A Case Of Apples And Oranges? 2016. http:\/\/healthaffairs.org\/blog\/2016\/09\/22\/budget-criteria-and-drug-value-assessments-a-case-of-apples-and-oranges\/<\/ext-link>."},{"key":"ref16","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/j.ijcard.2016.06.126","article-title":"PCSK9 inhibitors may improve cardiovascular outcomes\u2014Can we afford them?","volume":"220","author":"R Arbel","year":"2016","journal-title":"Int J Cardiol"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1161\/CIRCULATIONAHA.107.699579","article-title":"General cardiovascular risk profile for use in primary care the Framingham Heart Study","volume":"117","author":"RB D\u2019Agostino","year":"2008","journal-title":"Circulation"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1177\/0272989X06290495","article-title":"Preference-based EQ-5D index scores for chronic conditions in the United States","volume":"26","author":"PW Sullivan","year":"2006","journal-title":"Medical Decision Making"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"1740","DOI":"10.1056\/NEJMsa0804668","article-title":"Changes in the Incidence and Duration of Periods without Insurance","volume":"360","author":"DM Cutler","year":"2009","journal-title":"N Engl J Med"},{"key":"ref20","unstructured":"eHealth. eHealth Price Index. 2004. https:\/\/resources.ehealthinsurance.com\/ehealth-price-index<\/ext-link>."},{"key":"ref21","unstructured":"Centers for Medicare and Medicaid Services. Medicare Advantage Rate Statistics. 2015. https:\/\/www.cms.gov\/Medicare\/Health-Plans\/MedicareAdvtgSpecRateStats\/Ratebooks-and-Supporting-Data-Items\/2015Rates.html?DLPage=1&DLEntries=10&DLSort=0&DLSortDir=descending<\/ext-link>."},{"key":"ref22","unstructured":"Kaiser Family Foundation. The Medicare Part D Prescription Drug Benefit. 2014. http:\/\/files.kff.org\/attachment\/medicare-prescription-drug-benefit-fact-sheet<\/ext-link>."},{"key":"ref23","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1016\/j.jacc.2012.12.034","article-title":"Cost-effectiveness of statins for primary cardiovascular prevention in chronic kidney disease","volume":"61","author":"KF Erickson","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1161\/CIRCULATIONAHA.110.986349","article-title":"Cost-effectiveness of statin therapy for primary prevention in a low-cost statin era","volume":"124","author":"LD Lazar","year":"2011","journal-title":"Circulation"},{"key":"ref25","first-page":"6","article-title":"Use and Expenses for Office-Based Physician Visits by Specialty, 2009: Estimates for the US Civilian Noninstitutionalized Population","volume":"381","author":"KE Davis","year":"2012","journal-title":"Agency for Healthcare Research and Quality Statistical Brief"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1002\/hec.635","article-title":"Representing uncertainty: the role of cost-effectiveness acceptability curves","volume":"10","author":"E Fenwick","year":"2001","journal-title":"Health Econ"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1097\/MOL.0000000000000239","article-title":"PCSK9 inhibitors and cardiovascular disease: heralding a new therapeutic era","volume":"26","author":"MJ Chapman","year":"2015","journal-title":"Curr Opin Lipidol"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"2595","DOI":"10.1056\/NEJMp1512009","article-title":"Measuring the value of prescription drugs","volume":"373","author":"PJ Neumann","year":"2015","journal-title":"N Engl J Med"},{"key":"ref29","unstructured":"Desai R. Health Plans Are Interested in Tying Drug Payments to Patient Outcomes. 2016. http:\/\/avalere.com\/expertise\/life-sciences\/insights\/health-plans-are-interested-in-tying-drug-payments-to-patient-outcomes<\/ext-link>."}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0169761","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,10,23]],"date-time":"2018-10-23T09:44:44Z","timestamp":1540287884000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0169761"}},"subtitle":[],"editor":[{"given":"Dermot","family":"Cox","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2017,1,12]]},"references-count":29,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2017,1,12]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0169761","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,1,12]]}}}